Clinical Trials
146 trialsZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
Dana-Farber Cancer Institute
EPIK-B3
Novartis
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
MIMIR-mTNBC
Karolinska University Hospital
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
PRO1107 in Patients With Advanced Solid Tumors
Genmab
INTEGRAL
The Methodist Hospital Research Institute
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
neoMono
Palleos Healthcare GmbH
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Seagen Inc.
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Fusion Pharmaceuticals Inc.
Olinvacimab With Pembrolizumab in Patients With mTNBC
PharmAbcine
Néo-APBI-01
University Hospital, Grenoble
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
University of Chicago
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Regeneron Pharmaceuticals
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
National Institutes of Health Clinical Center (CC)
BIS-Program
Gustave Roussy, Cancer Campus, Grand Paris
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Transgene
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis
A Study of PF-06873600 in People With Cancer
Pfizer
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Mayo Clinic
MK-2140-002
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
ELEVATE TNBC
Gilead Sciences
TNBC
Zenith Epigenetics
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
M.D. Anderson Cancer Center
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
CytoDyn, Inc.
MGC018 With or Without MGA012 in Advanced Solid Tumors
MacroGenics
PEAR-TNBC
Ourotech, Inc.
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer
Sun Yat-sen University
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Hutchmed
A Study to Investigate LYL797 in Adults With Solid Tumors
Lyell Immunopharma, Inc.
START
Lyell Immunopharma, Inc.
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Roswell Park Cancer Institute
AVID100 in Advanced Epithelial Carcinomas
Formation Biologics
neoBREASTIM
Institut Curie
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
PERSEVERE
Hoosier Cancer Research Network
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Numab Therapeutics AG
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
Novartis
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
SK Life Science, Inc.
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC
Chipscreen Biosciences, Ltd.
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Seagen Inc.
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
G1 Therapeutics, Inc.